3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Unknown
2
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Depressive Disorder, Major
1
Depression
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
Psilocybin
×
Clear all
NCT05947383
2026-05-06
2Dose
Sunstone Medical
Phase 2
Active not recruiting
56 enrolled